Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOL-005
- Development stage
- Preclinical
- Lead developer
- Soley Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SOL-005 is an orally bioavailable small molecule therapeutic currently in preclinical development for the treatment of various oncology indications. Developed by Soley Therapeutics, the compound was identified using the company's proprietary AI-driven drug discovery platform, which integrates machine learning with biological datasets to identify novel therapeutic candidates. As of 2024, the specific molecular target and mechanism of action for SOL-005 remain undisclosed by the sponsor, though it is positioned as a targeted therapy within their cancer pipeline.
Beyond the preview
Go deeper on SOL-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOL-005.